Skip to main content

Monitoring of Coagulation: Management of Heparin and Protamine

  • Chapter
  • 175 Accesses

Abstract

Conventional cardiac surgery performed in medical centers throughout the world would be impossible without the use of cardiopulmonary bypass. This technology diverts a patient’s circulating blood volume as it enters the right atrium and effectively supplants the functions of both the heart and lungs. During this process, blood is exposed to thrombogenic surfaces in the oxygenator and pump tubing before returning to the patient. A safe and reliable method of anticoagulation followed by reversal of anticoagulation is, therefore, crucial to the performance of cardiopulmonary bypass and the completion of complex cardiac surgical procedures. Presently, the most effective means of providing temporary anticoagulation is with heparin.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Chargaff E, Olsen KB. Studies on the chemistry of blood coagulation, VI. Studies of the action of heparin and other anticoagulants. The influence of protamine on the anticoagulant effect in vivo.J Biol Chem 1938;125:671–676.

    CAS  Google Scholar 

  2. Gibbon JH Jr. The maintenance of life during experimental occlusion of the pulmonary artery followed by survival.Surg Gynecol Obstet 1939;69:602–614.

    Google Scholar 

  3. Gibbon JH Jr. Application of a mechanical heart and lung apparatus to cardiac surgery.Minn Med 1954;37:171–185.

    PubMed  Google Scholar 

  4. Gravlee GP. Anticoagulation for cardiopulmonary bypass. In: Gravlee GP, Davis RF, Utley JR, eds.Cardiopulmonary Bypass Principles and Procedures. Baltimore: Williams & Wilkins, 1993;340–380.

    Google Scholar 

  5. Bjork I, Olson ST, Shore JD. Molecular mechanisms of the accelerating effect of heparin on the reactions between antithrombin and clotting proteinases. In: Lane DA, Lindahl U, eds.Heparin Chemical and Biological Properties, Clinical Applications. Boca Raton, FL: CRC Press, 1989;229–255.

    Google Scholar 

  6. Tollefsen DM, Blinder MA. Heparin. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, eds.Hematology: Basic Principles and Practice. 2nd ed. New York: Churchill 1995;1807.

    Google Scholar 

  7. Bull SW, Huse WM, Brauer FS, Korpman RA. Heparin therapy during extracorporeal circulation, II. The use of a dose response curve to individualize heparin and protamine dosage.J Thorac Cardiovasc Surg 1975;69:685–689.

    PubMed  CAS  Google Scholar 

  8. Hoffman DL. Purification and large scale preparation of antithrombin III. Am J Med 1989;87(suppl 3B):23s–26s.

    Article  Google Scholar 

  9. Soloway HB, Christiansen TW. Heparin anticoagulation during cardiopulmonary bypass in an antithrombin III deficient patient. Implications relative to the etiology of heparin rebound.Am J Clin Path 1980;73:723–725.

    PubMed  CAS  Google Scholar 

  10. Phillips DE, Payne DK, Mills GM. Heparin induced thrombotic thrombocytopenia.Ann Pharmacother 1994;28:43–46.

    PubMed  CAS  Google Scholar 

  11. Bell WR, Royall RM. Heparin-associated thrombocytopenia: a comparison of three heparin preparations.N Engl J Med 1980;303:902–907.

    Article  PubMed  CAS  Google Scholar 

  12. Laser JL, Nichols WK, Silver D. Thrombocytopenia associated with heparin-associated antiplatelet antibodies.Arch Intern Med 1989;149:2285–2287.

    Article  Google Scholar 

  13. Ellison N, Edmunds LH, Coleman RW. Platelet aggregation following heparin and protamine administration.Anesthesiology 1978;48:65–68.

    Article  PubMed  CAS  Google Scholar 

  14. Stoelting RK, Henry DP, Verbur KM, et al. Haemodynamic changes and circulating histamine concentrations following protamine administration to patients and dogs.Can Anesth Soc J 1984;31:534–540.

    Article  CAS  Google Scholar 

  15. Horrow JC. Protamine: A review of its toxicity.J Anesth Analg 1985;64:348–361.

    CAS  Google Scholar 

  16. Haller JA, Ransdell HT, Stowens D, Rubel WF. Renal toxicity of polybrene in open-heart surgery.J Thorac Cardiovasc Surg 1962;44:486–491.

    Google Scholar 

  17. Zucker MS, Katz IR. Platelet factor 4: production, structure, and physiologic and immunologic action.Proc Soc Exp Biol Med 1991;198:693–702.

    PubMed  CAS  Google Scholar 

Download references

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag New York, Inc.

About this chapter

Cite this chapter

Lahey, S.J. (1998). Monitoring of Coagulation: Management of Heparin and Protamine. In: Krieger, K.H., Isom, O.W. (eds) Blood Conservation in Cardiac Surgery. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-2180-7_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-2180-7_10

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-94908-6

  • Online ISBN: 978-1-4612-2180-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics